For guidance, I suggest you research the development history of PD-1 and PD-L1 inhibitors and the speed with which they moved through clinical trials and FDA approval. You may also look at the projected sales of all PD-1s combined for estimated sales of ADU-S100.
but you rely on those analyst to pump up the value of stocks so you can successfully short them.. or in this case not successfully.
money is speech. What is Novartis saying with $400 million in milestone payments to Aduro? Is $400 million a typical agreement? Can you recall larger ones?
Will. Why do you think ADRO is climbing after trail failure? Market priced in LADD failure and lot of folks looking for long entry for ADU-S100 ride up.
I'm long ADRO for ADU-S100/CDN/STING which will advance through clinical trails as fast as PD-1's did and have projected sales equal to all the PD-1s combined. I don't give LADD or ADXS much thought.
markets pricing in possible Trump win. Until it becomes obvious he's going lose nothing's going to hold up. May not know til Oct. Every poll that has him closing the gap with Hillary will drop the market. Hillary is the only stable option left from a financial markets prospective